DOI:
10.1055/s-00043364
Pharmaceutical Fronts
LinksClose Window
References
Bauss F, Lechmann M, Krippendorff B-F. et al.
Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy.
Mol Oncol 2016;
10 (08) 1317-1329
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.